Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.
Robert L. Kirkman, MD
Advertisement
Articles by Robert L. Kirkman, MD
Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel
Advertisement
Latest Updated Articles
Dr. Kirkman on the Combination of PX-866 and DocetaxelPublished: June 27th 2012 | Updated:
Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast CancerPublished: June 24th 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5